These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 35624169)

  • 21. Immunisation strategies for viral diseases in developing countries.
    Ruff TA
    Rev Med Virol; 1999; 9(2):121-38. PubMed ID: 10386339
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Perspective of vaccine manufacturers on financing pediatric and adolescent vaccines in the United States.
    Shen AK; Rodewald LE; Birkhead GS
    Pediatrics; 2009 Dec; 124 Suppl 5():S540-7. PubMed ID: 19948586
    [TBL] [Abstract][Full Text] [Related]  

  • 23. "Reverse engineering" a formulary selection algorithm to determine the economic value of pentavalent and hexavalent combination vaccines.
    Sewell EC; Jacobson SH; Weniger BG
    Pediatr Infect Dis J; 2001 Nov; 20(11 Suppl):S45-56. PubMed ID: 11704724
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Physician and Patient Adjustment to Reference Pricing for Drugs.
    Robinson JC; Whaley C; Brown TT; Dhruva SS
    JAMA Netw Open; 2020 Feb; 3(2):e1920544. PubMed ID: 32022881
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Factors associated with the pricing of childhood vaccines in the U.S. public sector.
    Chen W; Messonnier M; Zhou F
    Health Econ; 2018 Feb; 27(2):252-265. PubMed ID: 28660666
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Global perspectives on vaccine financing.
    Berman S; Giffin RB
    Expert Rev Vaccines; 2004 Oct; 3(5):557-62. PubMed ID: 15485335
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Costs of introducing and delivering HPV vaccines in low and lower middle income countries: inputs for GAVI policy on introduction grant support to countries.
    Levin A; Wang SA; Levin C; Tsu V; Hutubessy R
    PLoS One; 2014; 9(6):e101114. PubMed ID: 24968002
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Procurement of Category 2 Vaccines in China.
    Zhuang JL; Wagner AL; Laffoon M; Lu YH; Jiang QW
    Vaccines (Basel); 2019 Aug; 7(3):. PubMed ID: 31450855
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of the profitability of adult vaccination in 13 private provider practices in the United States.
    Yarnoff B; Khavjou O; King G; Bates L; Zhou F; Leidner AJ; Shen AK
    Vaccine; 2019 Sep; 37(42):6180-6185. PubMed ID: 31495594
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incentive pricing and cost recovery at the basin scale.
    Ward FA; Pulido-Velazquez M
    J Environ Manage; 2009 Jan; 90(1):293-313. PubMed ID: 18241978
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pricing of HPV vaccines in European tender-based settings.
    Qendri V; Bogaards JA; Berkhof J
    Eur J Health Econ; 2019 Mar; 20(2):271-280. PubMed ID: 30051152
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective.
    Peny JM; Gleizes O; Covilard JP
    Vaccine; 2005 Aug; 23(37):4610-8. PubMed ID: 15979769
    [TBL] [Abstract][Full Text] [Related]  

  • 33. United States of America Department of Health and Human Services support for advancing influenza vaccine manufacturing in the developing world.
    Perdue ML; Bright RA
    Vaccine; 2011 Jul; 29 Suppl 1():A48-50. PubMed ID: 21684430
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Designing pediatric vaccine formularies and pricing pediatric combination vaccines using operations research models and algorithms.
    Jacobson SH; Sewell EC; Allwine DA; Medina EA; Weniger BG
    Expert Rev Vaccines; 2003 Feb; 2(1):15-9. PubMed ID: 12901593
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of United States and International Ophthalmic Drug Pricing.
    Gong D; Chang JS; Barbany M; Corcostegui BF; Kağan Değirmenci MF; Ishikawa H; Mammo Z; Ozmert E; Rossi T; Chang S
    Ophthalmology; 2019 Oct; 126(10):1358-1365. PubMed ID: 31146962
    [TBL] [Abstract][Full Text] [Related]  

  • 36. AIDS vaccines. IAVI issues blueprint to assure global access.
    AIDS Wkly; 2000 Jul; ():23-5. PubMed ID: 12322551
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccine financing and billing in practices serving adult patients: A follow-up survey.
    Lindley MC; Hurley LP; Beaty BL; Allison MA; Crane LA; Brtnikova M; Snow M; Bridges CB; Kempe A
    Vaccine; 2018 Feb; 36(8):1093-1100. PubMed ID: 29366706
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging issues in vaccine economics: perspectives from the USA.
    Lieu TA; Thompson KM; Prosser LA; O'Brien MA; Yusuf HR; Shefer AM; Weinstein MC; Rickert DL
    Expert Rev Vaccines; 2002 Dec; 1(4):433-42. PubMed ID: 12901581
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reference Pricing in Germany: Implications for U.S. Pharmaceutical Purchasing.
    Robinson JC; Panteli D; Ex P
    Issue Brief (Commonw Fund); 2019 Feb; 2019():1-8. PubMed ID: 30883061
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Improving global access to new vaccines: intellectual property, technology transfer, and regulatory pathways].
    Crager SE
    Rev Panam Salud Publica; 2015 Jan; 37(1):59-68. PubMed ID: 25791189
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.